Gilead Sciences 2Q11

2Q Revenues: $2.1 billion (+11%)

2Q Earnings: $746.2 million (+5%)

YTD Revenues: $4.1 billion (+1%)

YTD Earnings: $1.4 billion (-11%)

Comments: Antiviral product sales were up 11% to $1.8 billion in the quarter. Sales of Atripla increased 15% to $822.0 million, sales of Truvada were up 11% to $711.3 million, and sales of Viread increased 5% to $185.7 million. Sales of Letairis were up 22% to $73.6 million. Sales of Ranexa were up 42% to $86.1 million. Royalty, contract and other revenues were $97.7 million in the quarter, down 19% due to lower Tamiflu royalties from Roche.